$ODTX News

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation Transcript

Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026

Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026

UBS Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $27

Odyssey Therapeutics To Present Design Of Randomized, Double-Blind Phase 2a Trial Evaluating OD-001 In Combination With Vedolizumab In Patients With UC At ACG 2026 Annual Scientific Meeting

Raymond James Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $42

Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026

Odyssey Therapeutics, Inc. (ODTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply

HC Wainwright & Co. Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $44

JP Morgan Maintains Overweight on Odyssey Therapeutics, Raises Price Target to $29

Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Oppenheimer Reiterates Outperform on Odyssey Therapeutics, Maintains $40 Price Target

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Odyssey Therapeutics Q1 EPS $(6.77) Misses $(1.13) Estimate

Cantor Fitzgerald Initiates Coverage On Odyssey Therapeutics with Overweight Rating

TD Cowen Initiates Coverage On Odyssey Therapeutics with Buy Rating

Wedbush Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $30

JP Morgan Initiates Coverage On Odyssey Therapeutics with Overweight Rating, Announces Price Target of $26